Evidence map›Paper›PMID 25031714›Full record

ArticleInternational journal of clinical and experimental pathology2014

Stability of preclinical models of aggressive renal cell carcinomas.

Mariana Varna, Guilhem Bousquet, Irmine Ferreira, Marie Goulard, Morad El-Bouchtaoui, Pierre Mongiat Artus, Jérome Verine, Eric de Kerviler, Lucie Hernandez, Christophe Leboeuf and 7 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Mariana VarnaUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Guilhem BousquetUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Irmine FerreiraUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Marie GoulardUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France.
Morad El-BouchtaouiUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Pierre Mongiat ArtusUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Service d'Urologie Paris, F-75010 France.
Jérome VerineUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Eric de KervilerUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Service de Radiologie Paris, F-75010 France.
Lucie HernandezUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France.
Christophe LeboeufUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Bernard EscudierInstitut Gustave Roussy Villejuif, F-94805 France.
Luc LegrèsUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France.
Niclas SetterbladUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France.
Hany SolimanAP-HP-Hôpital Saint-Louis, Service de Biochimie Paris, F-75010 France.
Jean-Paul FeugeasAP-HP-Hôpital Saint-Louis, Service de Biochimie Paris, F-75010 France.
Anne JaninUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Philippe BertheauUniversité Paris Diderot, Sorbonne Paris Cité F-75010 Paris, France ; INSERM, U1165 Paris, F-75010 France ; AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie Paris, F-75010 France.
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRDélégation Paris 7 · FRInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal-cell carcinomas (RCC) are often resistant to conventional cytotoxic agents. Xenograft models are used for in vivo preclinical studies and drug development. The validity of these studies is highly dependent on the phenotypic and genotypic stability of the models. Here we assessed the stability of six aggressive human RCC xenografted in nude/NMRI mice. We compared the initial samples (P0), first (P1) and fifth (P5) passages for the following criteria: histopathology, immunohistochemistry for CK7, CD10, vimentin and p53, DNA allelic profiles using 10 microsatellites and CGH-array. Next we evaluated the response to sunitinib in primary RCC and corresponding xenografted RCC. We observed a good overall stability between primary RCC and corresponding xenografted RCC at P1 and P5 regarding histopathology and immunohistochemistry except for cytokeratin 7 (one case) and p53 (one case) expression. Out of 44 groups with fully available microsatellite data (at P0, P1 and P5), 66% (29 groups) showed no difference from P0 to P5 while 34% (15 groups) showed new or lost alleles. Using CGH-array, overall genomic alterations at P5 were not different from those of initial RCC. The xenografted RCC had identical response to sunitinib therapy compared to the initial human RCC from which they derive. These xenograft models of aggressive human RCC are clinically relevant, showing a good histological and molecular stability and are suitable for studies of basic biology and response to therapy.

Indexed as

Disease Models, AnimalAgedAnimalsCarcinoma, Renal CellFemaleHumansImmunohistochemistryKidney NeoplasmsMaleMiceMice, NudeMiddle AgedXenograft Model Antitumor Assayspreclinical modelrenal cell carcinomatumor genotypetumor phenotypeXenograft

Identifiers

PMID25031714
PMCPMC4097235
OpenAlexW1416610267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.